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See related editorial by Flannery et al., http://ccforum.com/content/18/5/509We read with interest the editorial by Flannery and col-
leagues [1], who proposed ‘a dose of healthy skepticism’
toward the findings of our Albumin Italian Outcome
Sepsis (ALBIOS) trial [2]. Although we feel uncertain
about where such ‘health’ may come from, we consider a
few extra words necessary. First, the rationale of the
subgroup analysis of 90-day mortality on septic shock
was based on the Kaplan-Meier estimates for 90-day
survivals of the entire study population, which tended to
separate between groups from day 30. Although this
observation was unexpected, it indicates the potential
beneficial effects of ancillary functions of albumin, besides
its oncotic property [3-5]. When patients with shock as
defined in a broader view (with cardiovascular Sequential
Organ Failure Assessment score of 1, 3, or 4; n = 1,303)
were considered, the beneficial effect of albumin on
90-day survival persisted (relative risk (RR) 0.88, 95%
confidence interval (CI) 0.78 to 0.99, P = 0.03) even
after adjustment for clinically relevant variables (RR
0.88, 95% CI 0.78 to 1.00, P = 0.049). Second, we agree
with the authors on the potential biases of an open-
label study. Nonetheless, we believe that the shorter
time to suspension of vasopressors observed in the
albumin as compared with the crystalloid group is a
solid finding, as supported by a higher or equal mean
arterial pressure over the study observed in the former
as compared with the latter group [2]. In conclusion,
the available data suggest not only that albumin may
be a safe alternative to crystalloids in patients with
severe sepsis but that it may be beneficial in those with* Correspondence: pietro.caironi@unimi.it
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article, unless otherwise stated.shock [6]. Further studies are warranted to confirm
this hypothesis.
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